All clinical trials

Background: Gravid diseases are complications in pregnancy. They include gestational diabetes and preeclampsia. These can cause problems with how a fetus grows. Being pregnant with twins can make complications more likely. Research suggests that changes in fetal soft tissue may be the earliest signs of growth problems. These tissue changes are in lean mass, fat mass, and organ size. 3D images might detect these changes earlier than 2D images. This could help manage gravid diseases. The NICHD Fetal Growth Studies - Singletons measured fetal growth for four racial groups, Caucasian, African American, Asian, and Hispanic. Fetuses of obese women and women with twins were also measured. 2D and 3D images were taken at various stages of pregnancy. Measurements were taken after birth. Researchers want to expand this study by measuring organ volumes and body composition by racial group and in twins. Objectives: To set standards for body composition and organ volumes by race. To understand the relationship between gravid diseases and changes in fetal body composition and organ volume over the course of pregnancy. To find out whether these are different for twins than for single pregnancies. Eligibility: Women who participated in the NICHD Fetal Growth Studies - Singletons and Twins. Design: The data will come from the NICHD Fetal Growth Studies - Singletons and Twins. Researchers will review scans taken in the previous study. They will take measurements from the scans.

A post-market registry evaluating the EmboTrap® Revascularization Device and CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter in acute ischemic stroke patients with confirmed intracranial large vessel occlusion.

The purpose of this trial is to explore the preliminary efficacy of Chiauranib monotherapy in patients with advanced or unresectable soft tissue sarcoma who failed standard therapy, and the safety of Chiauranib monotherapy in patients with advanced or unresectable soft tissue sarcoma who failed standard therapy and the relationship between potential biomarkers and preliminary efficacy.